Morepen Laboratories Ltd
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]
- Market Cap ₹ 2,619 Cr.
- Current Price ₹ 51.2
- High / Low ₹ 56.4 / 25.1
- Stock P/E 34.4
- Book Value ₹ 15.4
- Dividend Yield 0.00 %
- ROCE 8.57 %
- ROE 5.93 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 61.5 days to 104 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
289 | 326 | 367 | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,631 | |
270 | 295 | 318 | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,505 | |
Operating Profit | 19 | 31 | 49 | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 126 |
OPM % | 7% | 10% | 13% | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 8% |
13 | 6 | 4 | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 13 | |
Interest | 8 | 12 | 10 | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 3 |
Depreciation | 48 | 46 | 46 | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 31 |
Profit before tax | -24 | -21 | -3 | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 104 |
Tax % | -0% | -0% | -0% | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | |
-24 | -21 | -3 | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 76 | |
EPS in Rs | -0.53 | -0.46 | -0.06 | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.50 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 16% |
5 Years: | 19% |
3 Years: | 18% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 14% |
5 Years: | 6% |
3 Years: | 5% |
TTM: | 78% |
Stock Price CAGR | |
---|---|
10 Years: | 28% |
5 Years: | 25% |
3 Years: | 1% |
1 Year: | 96% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 16% |
Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 90 | 96 | 102 | 102 |
Reserves | 111 | 90 | 88 | 78 | 91 | 106 | 136 | 163 | 194 | 291 | 457 | 651 | 687 |
Preference Capital | 120 | 120 | 120 | 120 | 120 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
121 | 111 | 89 | 81 | 68 | 169 | 134 | 132 | 133 | 17 | 19 | 25 | 28 | |
225 | 215 | 223 | 240 | 276 | 173 | 226 | 230 | 246 | 460 | 499 | 332 | 377 | |
Total Liabilities | 547 | 506 | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,194 |
452 | 409 | 368 | 322 | 297 | 272 | 264 | 236 | 216 | 225 | 252 | 267 | 287 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 14 | 17 | 20 |
Investments | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
91 | 93 | 121 | 167 | 227 | 266 | 321 | 379 | 446 | 631 | 804 | 827 | 886 | |
Total Assets | 547 | 506 | 490 | 489 | 524 | 538 | 586 | 615 | 663 | 858 | 1,070 | 1,110 | 1,194 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
27 | 34 | 34 | 51 | 50 | 41 | 63 | 17 | 11 | 51 | -60 | -91 | |
-3 | -3 | -1 | -32 | -27 | -14 | -27 | -13 | -12 | -70 | -32 | -47 | |
-22 | -30 | -29 | -19 | -27 | -24 | -38 | -0 | 5 | 47 | 66 | 144 | |
Net Cash Flow | 2 | 1 | 4 | -0 | -4 | 3 | -1 | 4 | 4 | 28 | -26 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 44 | 44 | 42 | 51 | 66 | 57 | 73 | 64 | 59 | 56 | 59 | 68 |
Inventory Days | 77 | 68 | 56 | 55 | 51 | 65 | 76 | 69 | 91 | 82 | 96 | 87 |
Days Payable | 129 | 104 | 116 | 126 | 140 | 125 | 173 | 124 | 113 | 98 | 90 | 87 |
Cash Conversion Cycle | -8 | 8 | -17 | -20 | -23 | -3 | -24 | 9 | 37 | 40 | 65 | 69 |
Working Capital Days | -25 | -19 | -20 | -18 | -10 | -86 | -62 | -30 | -3 | 22 | 59 | 104 |
ROCE % | -6% | -3% | 1% | 3% | 8% | 9% | 9% | 8% | 10% | 25% | 25% | 9% |
Documents
Announcements
-
Regulation 40 Of SEBI (LODR) Reg. - Certificate From PCS
1d - Certificate obtained from practicing company secretary in compliance with Regulation 40 of SEBI (LODR) Regulations, Regulations, 2015, as amended.
- Compliance Certificate (RTA & Company) For The Financial Year Ended March 31, 2024 16 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 16 Apr
- Corporate Presentation 15 Apr
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Jul 2021Transcript PPT
-
May 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Sep 2020Transcript PPT
-
Jul 2020Transcript PPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Aug 2019TranscriptNotesPPT
-
May 2019Transcript PPT
-
Feb 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
Jun 2018TranscriptPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
Leadership in Anti-Asthmatic drug
The company is world leader in Loratadine (140 MT) and has achieved the leadership position of being one of the largest suppliers of anti-asthmatic drug, Montelukast Sodium (85 MT). It is a prominent player in commercial production of drugs Atorvastatin calcium (120 MT), Rosuvastatin calcium of anti-hypercholesterolemic series, Fexofenadine Hydrochloride of antihistamine series, Olmesartan of anti-hypertensive series & their intermediates. [1] [2]